Effect of the P-Selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial.
COVID-19
P-selectin
crizanlizumab
Journal
Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
medline:
2
8
2023
pubmed:
25
6
2023
entrez:
25
6
2023
Statut:
ppublish
Résumé
COVID-19 has been associated with endothelial injury, resultant microvascular inflammation and thrombosis. Activated endothelial cells release and express P-selectin and von Willebrand factor, both of which are elevated in severe COVID-19 and may be implicated in the disease pathophysiology. We hypothesized that crizanlizumab, a humanized monoclonal antibody to P-selectin, would reduce morbidity and death in patients hospitalized for COVID-19. An international, adaptive, randomized controlled platform trial, funded by the National Heart, Lung, and Blood Institute, randomly assigned 422 patients hospitalized with COVID-19 with moderate or severe illness to receive either a single infusion of the P-selectin inhibitor crizanlizumab (at a dose of 5 mg/kg) plus standard of care or standard of care alone in an open-label 1:1 ratio. The primary outcome was organ support-free days, evaluated on an ordinal scale consisting of the number of days alive free of organ support through the first 21 days after trial entry. The study was stopped for futility by the data safety monitoring committee. Among 421 randomized patients with known 21-day outcomes, 163 patients (77%) randomized to the crizanlizumab plus standard-of-care arm did not require any respiratory or cardiovascular organ support compared with 169 (80%) in the standard-of-care-alone arm. The adjusted odds ratio for the effect of crizanlizumab on organ support-free days was 0.70 (95% CI, 0.43-1.16), where an odds ratio >1 indicates treatment benefit, yielding a posterior probability of futility (odds ratio <1.2) of 98% and a posterior probability of inferiority (odds ratio <1.0) of 91%. Overall, there were 37 deaths (17.5%) in the crizanlizumab arm and 27 deaths (12.8%) in the standard-of-care arm (hazard ratio, 1.33 [95% CrI, 0.85-2.21]; [probability of hazard ratio>1] = 0.879). Crizanlizumab, a P-selectin inhibitor, did not result in improvement in organ support-free days in patients hospitalized with COVID-19. URL: https://www. gov; Unique identifier: NCT04505774.
Sections du résumé
BACKGROUND
COVID-19 has been associated with endothelial injury, resultant microvascular inflammation and thrombosis. Activated endothelial cells release and express P-selectin and von Willebrand factor, both of which are elevated in severe COVID-19 and may be implicated in the disease pathophysiology. We hypothesized that crizanlizumab, a humanized monoclonal antibody to P-selectin, would reduce morbidity and death in patients hospitalized for COVID-19.
METHODS
An international, adaptive, randomized controlled platform trial, funded by the National Heart, Lung, and Blood Institute, randomly assigned 422 patients hospitalized with COVID-19 with moderate or severe illness to receive either a single infusion of the P-selectin inhibitor crizanlizumab (at a dose of 5 mg/kg) plus standard of care or standard of care alone in an open-label 1:1 ratio. The primary outcome was organ support-free days, evaluated on an ordinal scale consisting of the number of days alive free of organ support through the first 21 days after trial entry.
RESULTS
The study was stopped for futility by the data safety monitoring committee. Among 421 randomized patients with known 21-day outcomes, 163 patients (77%) randomized to the crizanlizumab plus standard-of-care arm did not require any respiratory or cardiovascular organ support compared with 169 (80%) in the standard-of-care-alone arm. The adjusted odds ratio for the effect of crizanlizumab on organ support-free days was 0.70 (95% CI, 0.43-1.16), where an odds ratio >1 indicates treatment benefit, yielding a posterior probability of futility (odds ratio <1.2) of 98% and a posterior probability of inferiority (odds ratio <1.0) of 91%. Overall, there were 37 deaths (17.5%) in the crizanlizumab arm and 27 deaths (12.8%) in the standard-of-care arm (hazard ratio, 1.33 [95% CrI, 0.85-2.21]; [probability of hazard ratio>1] = 0.879).
CONCLUSIONS
Crizanlizumab, a P-selectin inhibitor, did not result in improvement in organ support-free days in patients hospitalized with COVID-19.
REGISTRATION
URL: https://www.
CLINICALTRIALS
gov; Unique identifier: NCT04505774.
Identifiants
pubmed: 37356038
doi: 10.1161/CIRCULATIONAHA.123.065190
pmc: PMC10373640
doi:
Substances chimiques
crizanlizumab
L7451S9126
P-Selectin
0
Banques de données
ClinicalTrials.gov
['NCT04505774']
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
381-390Subventions
Organisme : NHLBI NIH HHS
ID : OT2 HL156812
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
JACC Basic Transl Sci. 2021 Dec;6(12):935-945
pubmed: 34904132
Cell. 1993 Aug 13;74(3):541-54
pubmed: 7688665
Cardiovasc Res. 2015 Aug 1;107(3):331-9
pubmed: 25994174
N Engl J Med. 2021 Aug 26;385(9):790-802
pubmed: 34351721
Lancet Haematol. 2020 Aug;7(8):e575-e582
pubmed: 32619411
J Vasc Surg. 2005 Aug;42(2):329-36
pubmed: 16102635
Eur Heart J. 2020 Sep 1;41(32):3038-3044
pubmed: 32882706
J Thromb Haemost. 2022 May;20(5):1056-1066
pubmed: 35243742
J Exp Med. 1995 Feb 1;181(2):669-75
pubmed: 7530761
Exp Mol Pathol. 2002 Feb;72(1):68-76
pubmed: 11784125
Circulation. 2000 Oct 17;102(16):1931-6
pubmed: 11034941
N Engl J Med. 2017 Feb 2;376(5):429-439
pubmed: 27959701
Circulation. 2020 Oct 27;142(17):1609-1611
pubmed: 32877231
JCI Insight. 2020 Jun 4;5(11):
pubmed: 32329756
Blood. 2015 Jul 9;126(2):242-6
pubmed: 25979951
Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11452-7
pubmed: 10500197
Circ Res. 2020 Sep 11;127(7):945-947
pubmed: 32757722
JAMA. 2022 Jan 18;327(3):227-236
pubmed: 35040887